The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Steven Chmura and Sean Pitroda.
Connection Strength

2.622
  1. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022 Nov 28.
    View in: PubMed
    Score: 0.225
  2. Linear accelerator-based stereotactic radiosurgery for glossopharyngeal neuralgia is safe and effective - Report of two cases. J Radiosurg SBRT. 2022; 8(2):151-153.
    View in: PubMed
    Score: 0.211
  3. Evaluation of Initial Metastatic Tumor Location and Radiation Response to Determine Outcomes in Patients Who Received Combination Stereotactic Body Radiotherapy and Immunotherapy for NSCLC. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):e449.
    View in: PubMed
    Score: 0.209
  4. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
    View in: PubMed
    Score: 0.208
  5. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
    View in: PubMed
    Score: 0.206
  6. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
    View in: PubMed
    Score: 0.194
  7. A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):189-195.
    View in: PubMed
    Score: 0.190
  8. Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol. 2019 08; 20(8):e434-e442.
    View in: PubMed
    Score: 0.178
  9. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
    View in: PubMed
    Score: 0.161
  10. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 07 15; 122(14):2242-50.
    View in: PubMed
    Score: 0.143
  11. Radiotherapy Enhances Metastasis Through Immune Suppression by inducing PD-L1 and MDSC in distal sites. Clin Cancer Res. 2024 Mar 01.
    View in: PubMed
    Score: 0.061
  12. Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials. Int J Radiat Oncol Biol Phys. 2024 Apr 01; 118(5):1519-1530.
    View in: PubMed
    Score: 0.061
  13. Epitranscriptional regulation of TGF-ß pseudoreceptor BAMBI by m6A/YTHDF2 drives extrinsic radioresistance. J Clin Invest. 2023 Dec 15; 133(24).
    View in: PubMed
    Score: 0.060
  14. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023 07 10; 41(7):1294-1308.e8.
    View in: PubMed
    Score: 0.058
  15. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol. 2022 09; 19(9):585-599.
    View in: PubMed
    Score: 0.055
  16. Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):645-654.
    View in: PubMed
    Score: 0.055
  17. Prospective Evaluation of Stereotactic Body Radiotherapy and Immunotherapy for Mediastinal and Hilar Lymph Node Metastases. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):S10.
    View in: PubMed
    Score: 0.052
  18. Stereotactic Body Radiation Therapy and Immunotherapy in Abdominal and Pelvic Lymph Node Metastases. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):S58.
    View in: PubMed
    Score: 0.052
  19. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.051
  20. Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. J Exp Med. 2021 03 01; 218(3).
    View in: PubMed
    Score: 0.050
  21. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021 02 24; 13(582).
    View in: PubMed
    Score: 0.050
  22. Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):17-26.
    View in: PubMed
    Score: 0.048
  23. Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat Commun. 2019 09 02; 10(1):3959.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.